Aspen Announces Additional Share Buyback and Sets Cancellation Before End-November 2026
Key Facts
In a November 5, 2026 disclosure, Aspen announced an additional share buyback and said an application to delist and cancel the repurchased shares would be submitted to the Johannesburg Stock Exchange, with completion expected before the end of November 2026. The value of the buyback program and the number of shares covered could not be verified from a reliable open source, so reported figures for the transaction’s value or size cannot be confirmed. The company said share buybacks remain its preferred way to return capital to shareholders as part of the allocation of proceeds from the Ovestin transaction. The disclosure thus places the capital-return plan in the context of a broader deal to reshape Aspen’s product portfolio. Cancellation of the shares is the next step specified in the announcement.
Aspen announced on November 2, 2026, that it had sold the European marketing rights and related intellectual property for Ovestin to Ennogen for 197 million euros, in addition to inventory valued at about 4 million euros. Reuters reported that the company said the transaction proceeds would be subject to its capital allocation policy, linking the deal to its decision on returning funds to shareholders without establishing that the proceeds financed the buybacks. According to Aspen, share buybacks remain its preferred capital-return option. This arrangement distinguishes the specified consideration for the sale of the rights and inventory from the amount the company may actually allocate to repurchases. It also means that the allocation decision, rather than completion of the sale alone, determines where the proceeds go.
Aspen is not exiting the Ovestin supply chain entirely after selling the European rights; it will continue to manufacture and supply the product’s active pharmaceutical ingredient and cream formulation to Ennogen under an initial agreement lasting 10 years. The company will also provide strategic support services for 5 years for 1 million euros per month, alongside transitional services that may continue for up to 3 years. These arrangements preserve Aspen’s role in manufacturing and supply after the marketing rights and intellectual property transfer to Ennogen. The agreements also set different periods for the relationship between the parties: an initial manufacturing and supply term, a strategic support period, and transitional services with a stated maximum duration. Those operational commitments remain part of the transaction’s context, with Aspen saying the proceeds will be subject to its capital allocation policy.
The transaction follows Ovestin generating revenue of about 756 million rand and after-tax profit of 238 million rand for Aspen in fiscal 2026. These figures show the scale of the product’s financial activity during that year, as the company sells its European rights while continuing to manufacture and supply the product under the announced agreement. The sale of the rights and inventory provides specified consideration in euros, while the manufacturing and services contracts allow Aspen’s relationship with the product to continue after the transaction. The company said buybacks remain its preferred means of returning capital, but the value of the buyback itself could not be verified from a reliable open source. The available disclosure therefore does not establish that the sale proceeds have already been converted into a specific amount returned to shareholders.
In the market, Aspen shares rose 2.08% in the November 5, 2026, session, when the additional buyback was announced. The move reflects the session in which the announcement was made, while the evidence does not provide verified figures for the closing price or the session high on November 10. The next procedural step is to submit an application to the Johannesburg Stock Exchange to delist and cancel the repurchased shares; the disclosure expected this to be completed before the end of November 2026. This timetable links the cancellation to an exchange procedure after the buyback, while the disclosure gave no more specific date. Aspen says the buyback is its preferred capital-return option under its policy for allocating the Ovestin transaction proceeds.